APA (7th ed.) Citation

KM, L., EM, B., SS, J., GW, I., H, M., FG, L., . . . KI, S. (2022). Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors. Cancer research, 82(5), 819. https://doi.org/10.1158/0008-5472.CAN-21-1843

Chicago Style (17th ed.) Citation

KM, Lappin, et al. "Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors." Cancer Research 82, no. 5 (2022): 819. https://doi.org/10.1158/0008-5472.CAN-21-1843.

MLA (9th ed.) Citation

KM, Lappin, et al. "Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors." Cancer Research, vol. 82, no. 5, 2022, p. 819, https://doi.org/10.1158/0008-5472.CAN-21-1843.